InMed Pharmaceuticals Inc Share Price Canadian Securities Exchange
Equities
IN
CA4576371062
Biotechnology & Medical Research
Sales 2024 * | 7.3M 5.34M 444M | Sales 2025 * | 9.12M 6.67M 554M | Capitalization | 2.51M 1.84M 153M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.34 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.28 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.01% |
Latest transcript on InMed Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Chief Operating Officer | - | 05/18/05 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11/22/11 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Andrew Hull
CHM | Chairman | 61 | 12/16/12 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |